Open AccessRomidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia
Author(s) -
Laurence C. Cheung,
Mark N Cruickshank,
Anastasia Hughes,
Sarguni Singh,
Grace-Alyssa Chua,
Jette Ford,
Emanuela Ferrari,
Joyce Oommen,
Sébastien Malinge,
Richard B. Lock,
Ursula R. Kees,
Rishi S. Kotecha
Publication year - 2019
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2018.192906
Subject(s) - romidepsin , histone deacetylase , in vivo , cancer research , cytarabine , panobinostat , medicine , lymphoblastic leukemia , leukemia , pharmacology , chemistry , histone , biology , myeloid leukemia , genetics , biochemistry , gene